The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

EC approves Keytruda + trastuzumab + chemo for first-line treatment of GEJ cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The European Commission approved Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2-positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

EC approves Lynparza + Imfinzi for pMMR endometrial cancer

The European Commission approved Imfinzi (durvalumab) and Lynparza (olaparib) as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as first-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch repair proficient disease. Imfinzi plus chemotherapy followed by Imfinzi alone has been approved for patients with mismatch repair deficient disease.
Drugs & Targets

EC grants conditional marketing authorization for Tepkinly for r/r FL

The European Commission granted conditional marketing authorization for Tepkinly (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. Tepkinly is the only subcutaneous T-cell engaging bispecific antibody approved to treat both r/r FL and r/r diffuse large B-cell lymphoma in the EU, as well as the European Economic Area countries (Iceland, Liechtenstein, Norway) and Northern Ireland.
Clinical Roundup

Sarclisa combination improves PFS in newly diagnosed MM in phase III trial

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab), in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen), significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly-diagnosed multiple myeloma not eligible for transplant. 
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account